After a median follow-up of 17 months ( IQR 15-18 ) , the primary endpoint occurred in 27 ( 4 % ) patients in the interruption group and 24 ( 4 % ) patients in the continuation group ( hazard ratio [ HR ] 117 [ 95 % CI 068-203 ] ; p = 058 ) .